Compare · AZN vs SYRE
AZN vs SYRE
Side-by-side comparison of AstraZeneca PLC (AZN) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $262.48B, about 29.2x SYRE ($8.98B).
- Over the past year, AZN is down 10.2% and SYRE is up 499.5% - SYRE leads by 509.7 points.
- AZN has hit the wire 7 times in the past 4 weeks while SYRE has been quiet.
- AZN has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- AstraZeneca PLC
- Spyre Therapeutics Inc.
- Price
- $169.00+0.41%
- $102.18+2.16%
- Market cap
- $262.48B
- $8.98B
- 1M return
- -7.41%
- +18.47%
- 1Y return
- -10.25%
- +499.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2016
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 10
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest SYRE
- Chief Financial Officer Burrows Scott L exercised 7,500 shares at a strike of $14.50 and sold $658,040 worth of shares (7,500 units at $87.74) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Sloan Sheldon exercised 8,334 shares at a strike of $27.46 and sold $730,896 worth of shares (8,334 units at $87.70) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Turtle Cameron sold $1,315,346 worth of shares (15,000 units at $87.69) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 582,540 units (SEC Form 4)
- Spyre Therapeutics Announces Grants of Inducement Awards
- Chief Financial Officer Burrows Scott L exercised 15,000 shares at a strike of $14.50 and sold $1,307,000 worth of shares (15,000 units at $87.13) (SEC Form 4)
- SEC Form S-3ASR filed by Spyre Therapeutics Inc.
- Director Fairmount Funds Management Llc converted options into 666,680 shares and sold $399,658,667 worth of shares (4,684,781 units at $85.31) (SEC Form 4)
- Director Henderson Michael Thomas sold $2,000,000 worth of shares (20,000 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 68,606 units (SEC Form 4)
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients